CL2008001238A1 - Anticuerpo antagonista aislado anti-receptor grig/pro362/jam4/stigma murino con numero de deposito atcc pat-8298; composicion farmaceutica; uso medico para inhibir la entrada celulst dependiente del complemento mediada por crig de un patogeno intracelular (pi), o para prevenir o tratar una enfermedadad infeccionsa mediada por un pi - Google Patents

Anticuerpo antagonista aislado anti-receptor grig/pro362/jam4/stigma murino con numero de deposito atcc pat-8298; composicion farmaceutica; uso medico para inhibir la entrada celulst dependiente del complemento mediada por crig de un patogeno intracelular (pi), o para prevenir o tratar una enfermedadad infeccionsa mediada por un pi

Info

Publication number
CL2008001238A1
CL2008001238A1 CL2008001238A CL2008001238A CL2008001238A1 CL 2008001238 A1 CL2008001238 A1 CL 2008001238A1 CL 2008001238 A CL2008001238 A CL 2008001238A CL 2008001238 A CL2008001238 A CL 2008001238A CL 2008001238 A1 CL2008001238 A1 CL 2008001238A1
Authority
CL
Chile
Prior art keywords
mediated
crig
complement
inhibit
pharmaceutical composition
Prior art date
Application number
CL2008001238A
Other languages
English (en)
Spanish (es)
Inventor
Van Lookeren Campagne Menno
Original Assignee
Genentech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=39645433&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CL2008001238(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Genentech Inc filed Critical Genentech Inc
Publication of CL2008001238A1 publication Critical patent/CL2008001238A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Virology (AREA)
  • Veterinary Medicine (AREA)
  • Molecular Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Immunology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biomedical Technology (AREA)
  • Zoology (AREA)
  • General Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • AIDS & HIV (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CL2008001238A 2007-05-01 2008-04-30 Anticuerpo antagonista aislado anti-receptor grig/pro362/jam4/stigma murino con numero de deposito atcc pat-8298; composicion farmaceutica; uso medico para inhibir la entrada celulst dependiente del complemento mediada por crig de un patogeno intracelular (pi), o para prevenir o tratar una enfermedadad infeccionsa mediada por un pi CL2008001238A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US91534007P 2007-05-01 2007-05-01

Publications (1)

Publication Number Publication Date
CL2008001238A1 true CL2008001238A1 (es) 2008-11-07

Family

ID=39645433

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2008001238A CL2008001238A1 (es) 2007-05-01 2008-04-30 Anticuerpo antagonista aislado anti-receptor grig/pro362/jam4/stigma murino con numero de deposito atcc pat-8298; composicion farmaceutica; uso medico para inhibir la entrada celulst dependiente del complemento mediada por crig de un patogeno intracelular (pi), o para prevenir o tratar una enfermedadad infeccionsa mediada por un pi

Country Status (16)

Country Link
US (1) US20090162356A1 (https=)
EP (1) EP2152749A1 (https=)
JP (1) JP2010526076A (https=)
KR (1) KR20100018523A (https=)
CN (1) CN101675078A (https=)
AR (1) AR066375A1 (https=)
AU (1) AU2008247958A1 (https=)
BR (1) BRPI0810926A2 (https=)
CA (1) CA2682835A1 (https=)
CL (1) CL2008001238A1 (https=)
IL (1) IL201165A0 (https=)
MX (1) MX2009011407A (https=)
PE (1) PE20090239A1 (https=)
RU (1) RU2009144280A (https=)
WO (1) WO2008137338A1 (https=)
ZA (1) ZA200906812B (https=)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20080124355A1 (en) 2006-09-22 2008-05-29 David Gordon Bermudes Live bacterial vaccines for viral infection prophylaxis or treatment
RU2553517C2 (ru) * 2008-05-06 2015-06-20 Дженентек, Инк. Варианты crig с созревшей аффинностью
US8241623B1 (en) 2009-02-09 2012-08-14 David Bermudes Protease sensitivity expression system
US8524220B1 (en) 2010-02-09 2013-09-03 David Gordon Bermudes Protease inhibitor: protease sensitivity expression system composition and methods improving the therapeutic activity and specificity of proteins delivered by bacteria
US8771669B1 (en) 2010-02-09 2014-07-08 David Gordon Bermudes Immunization and/or treatment of parasites and infectious agents by live bacteria
US9597379B1 (en) 2010-02-09 2017-03-21 David Gordon Bermudes Protease inhibitor combination with therapeutic proteins including antibodies
US9593339B1 (en) 2013-02-14 2017-03-14 David Gordon Bermudes Bacteria carrying bacteriophage and protease inhibitors for the treatment of disorders and methods of treatment
CN104231085B (zh) * 2013-09-05 2017-03-15 复旦大学附属肿瘤医院 靶向特异性补体系统抑制剂、其制备方法及应用
US10676723B2 (en) 2015-05-11 2020-06-09 David Gordon Bermudes Chimeric protein toxins for expression by therapeutic bacteria
CN105924515B (zh) * 2016-04-25 2019-06-14 中国人民解放军第三军医大学 免疫共刺激分子vsig4激活性表位肽、单克隆抗体及其制备方法和应用
US11129906B1 (en) 2016-12-07 2021-09-28 David Gordon Bermudes Chimeric protein toxins for expression by therapeutic bacteria
US11180535B1 (en) 2016-12-07 2021-11-23 David Gordon Bermudes Saccharide binding, tumor penetration, and cytotoxic antitumor chimeric peptides from therapeutic bacteria
WO2019005817A2 (en) * 2017-06-26 2019-01-03 Bio-Techne Corporation HYBRIDOMIC CLONES, MONOCLONAL ANTIBODIES DIRECTED AGAINST VSIG-4, AND METHODS OF MAKING AND USING SAME
CN113423728B (zh) * 2018-09-28 2024-03-01 优特力克斯有限公司 抗人vsig4抗体及其应用
US20220233756A1 (en) * 2019-05-17 2022-07-28 George A. Herzlinger Methods and systems for treating microbial disease
US20220306736A1 (en) * 2019-09-04 2022-09-29 Y-Biologics Inc. Anti-vsig4 antibody or antigen binding fragment and uses thereof
US20240158503A1 (en) 2021-03-03 2024-05-16 Pierre Fabre Medicament Anti-vsig4 antibody or antigen binding fragment and uses thereof
USD1121924S1 (en) * 2023-12-08 2026-04-14 3Rd Wave Apparel Pty Ltd Cap

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8088386B2 (en) * 1998-03-20 2012-01-03 Genentech, Inc. Treatment of complement-associated disorders

Also Published As

Publication number Publication date
WO2008137338A1 (en) 2008-11-13
CN101675078A (zh) 2010-03-17
IL201165A0 (en) 2010-05-17
ZA200906812B (en) 2010-12-29
AR066375A1 (es) 2009-08-12
PE20090239A1 (es) 2009-03-19
AU2008247958A1 (en) 2008-11-13
EP2152749A1 (en) 2010-02-17
US20090162356A1 (en) 2009-06-25
CA2682835A1 (en) 2008-11-13
RU2009144280A (ru) 2011-06-10
KR20100018523A (ko) 2010-02-17
BRPI0810926A2 (pt) 2014-11-04
MX2009011407A (es) 2009-11-05
JP2010526076A (ja) 2010-07-29

Similar Documents

Publication Publication Date Title
CL2008001238A1 (es) Anticuerpo antagonista aislado anti-receptor grig/pro362/jam4/stigma murino con numero de deposito atcc pat-8298; composicion farmaceutica; uso medico para inhibir la entrada celulst dependiente del complemento mediada por crig de un patogeno intracelular (pi), o para prevenir o tratar una enfermedadad infeccionsa mediada por un pi
AR119754A2 (es) Anticuerpos anti-fgfr3 y métodos que los utilizan
MX2021001957A (es) Compuestos de degradacion y metodos de uso del receptor de tropomiosina quinasa (trk).
CY1120417T1 (el) Μεθοδοι για τη μειωση των επιπεδων των βασεοφιλων
BRPI0510170B8 (pt) composto, composição farmacêutica para o tratamento de doenças mediadas pelo receptor muscarínico de acetilcolina e uso do composto
CL2007002018A1 (es) Compuestos derivados de isoxazolinas sustituidas; procedimiento de preparacion; composicion farmaceutica; y uso del compuesto para el tratamiento de una enfermedad causada por un aumento en la proliferacion celular.
AR094740A1 (es) Antiadhesión de leucocitos para mitigar los potenciales eventos adversos causados por los dominios de unión específicos de cd3
DOP2006000162A (es) Nuevos anticuerpos anti-madcan
NO20084458L (no) IL-8-reseptorantagonister
CL2018003608A1 (es) Anticuerpo aislado o fragmento de unión a antígeno del mismo que se une específicamente interleucina-25 hjumana (il-2525); composición farmacéutica que lo comprende; uso de dicha composición farmacéutica para tratar una enfermedad o trastorno asociado con la actividad o expresión de il-25. (divisional solicitud 201700703)
RU2017105515A (ru) Сигнальная система
CL2018000750A1 (es) Método de redireccionamiento de linfocitos t para el tratamiento de la infección por vih
TW201129378A (en) Materials and methods for treating or preventing HER-3 associated diseases
EA201170636A1 (ru) Антагонисты толл-подобного рецептора 3
EA201290254A1 (ru) Антагонисты il-17a
BRPI0921999B8 (pt) uso de uma quantidade terapeuticamente eficaz de células tronco placentárias
CL2008002228A1 (es) Compuestos derivados de imidazopiridinonas, agonista de tlr7; procedimiento de preparacion; compuestos intermediarios; composiicon farmaceutica que los comprende; y uso en infecciones virales, bacterianas y fungicas.
ECSP10010322A (es) Anticuerpos contra el virus de la influenza y métodos de uso de los mismos
AR044927A1 (es) Metodos y composiciones para tratar la artritis reumatoidea
WO2010056898A3 (en) Rapid expression cloning of human monoclonal antibodies from memory b cells
ECSP109889A (es) Composiciones terapeuticas y usos de las mismas
BR112013005145A2 (pt) anticorpos anti-cxcl13 e métodos para seu uso
EA200900767A1 (ru) Антагонистические антитела против ephb3
CL2012003745A1 (es) Compuestos derivados de aminopirazoloquinazolinas, como inhibidores frente a la actividad fosforilante del receptor igf-1 localizado en membranas celulares; preparacion farmaceutica que los contiene; y su uso en el tratamiento y/o prevencion de cancer, infecciones, enfermedades inflamatorias y autoinmunitarias.
MX2023009769A (es) Terapias de combinación con anticuerpos anti-cd38 e inhibidores de parp o de los receptores de adenosina.